Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19390009 | 0.88 | HSD17B10 (0.36) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL30742980 | 0.86 | PTPN1 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL16824579 | 0.86 | PTPN1 (0.38) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL5782185 | 0.85 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL193268 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL185992 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL5782181 | 0.85 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL1848946 | 0.85 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL29514298 | 0.85 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31759047 | 0.83 | TSHR (0.38) | HSD17B10SMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| CN-119462659-A | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-113874079-B | Bridged tricyclic carbamoyl pyridone compounds and pharmaceutical uses thereof | 吉利德科学公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3938047-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113874079-A | Bridged tricyclic carbamoylpyridone compounds and pharmaceutical use thereof | 吉利德科学公司 | 2021-12-31 | — | — | CN | disclosed |
| WO-2021212039-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200317689-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| WO-2020197991-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020197991-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| US-9776964-B2 | Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators | ELI LILLY AND COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3083562-B1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | ELI LILLY AND COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | HSD17B10 1938/4885SMN1; SMN2 4187/4885CHRM2 231/4885 |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B10 2485/4885SMN1; SMN2 1498/4885CHRM2 2572/4885 |
| US-20160272585-A1 | Phenoxyethyl Cyclic Amine Derivatives and Their Activity as EP4 Receptor Modulators | PTGER4, PTGER1, GPR4 | HSD17B10 3686/4885SMN1; SMN2 4442/4885CHRM2 109/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885CHRM2 4479/4885 |
| US-12227520-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | HSD17B10 2083/4885SMN1; SMN2 4162/4885CHRM2 247/4885 |
| US-20230203061-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | HSD17B10 2083/4885SMN1; SMN2 4162/4885CHRM2 247/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885CHRM2 4479/4885 |
| US-20200317689-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, XDH | HSD17B10 2083/4885SMN1; SMN2 4162/4885CHRM2 247/4885 |
| US-11084832-B2 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use | ZYX, CCNY, XDH | HSD17B10 2083/4885SMN1; SMN2 4162/4885CHRM2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.